Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case

Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. settled their patent lawsuit over Samsung’s biosimilar version of Eylea, leaving Amgen Inc. as the lone remaining defendant in Regeneron’s once-sprawling litigation campaign over the blockbuster eye-disease drug.

Samsung Bioepis and Regeneron agreed to dismiss all claims and counterclaims between them, lift a July 2024 injunction that had barred Samsung Bioepis’ biosimilar, and release the associated payment held as a bond, according to Judge Thomas S. Kleeh’s order issued Thursday in the US District Court for the Northern District of West Virginia.

The deal followed earlier settlements with Celltrion Inc., Formycon AG, ...